» WhiteLab Genomics, specialist in AI for genomic therapies, raises 10 million euros MyPharma Editions

» WhiteLab Genomics, specialist in AI for genomic therapies, raises 10 million euros MyPharma Editions

Posted on Thursday September 15th, 2022

WhiteLab Genomics, passed by Y-Combinator, has developed a predictive software simulation AI platform for the design of gene and cell therapies. WhiteLab Genomics announces today a fundraising of 10 million euros. The round was led by Omnes Capital, one of France’s leading venture capital firms, and Debiopharm, an independent biopharmaceutical company based in Switzerland.

WhiteLab Genomics aims to revolutionize the development of genomic therapies using public and private data and in-house AI algorithms. The company supports its customers in the in-silico development phases, enabling them to rapidly develop target vectors, therapeutic sequences, and bring genomics-based therapies to market more quickly.

This fundraising will make it possible to continue the development of WhiteLab Genomics’ AI-based platform, to develop its R&D team and to finance its expansion in the United States.

The company was founded in 2019 by David Del Bourgo and Julien Cottineau, experts in the development and commercialization of genomic drugs. Together, they established WhiteLab Genomics headquarters in Paris, and are currently setting up their US operations in Cambridge, MA.

“We are seeing strong demand from leading pharmaceutical and biotechnology companies across many healthcare sectors. They all understand the enormous potential of genomic therapies and the significant role of data and AI when it comes to advancing and developing healthcare. WhiteLab Genomics offers its expertise, specific datasets and algorithms dedicated to their therapies. Today, to best meet the needs of our prospects and our customers, we must develop all aspects of our business. explains David DelBourgo, co-founder and CEO of WhiteLab Genomics.

Currently, WhiteLab Genomics’ customers include biotechnology and pharmaceutical companies in Europe and the United States, which provide solutions for new drug development programs. These companies are working on therapies based on RNA, DNA and cells, among other things. WhiteLab Genomics also collaborates with world renowned laboratories such as INSERM and Généthon, and has been selected by Y-Combinator in their Winter 2022 promotion (W22). The company has been honored with numerous awards (Galien Foundation, Alumni New Venture Fund from the University of Chicago’s Polsky Innovation Center), and was selected by Station F to be part of the 2019 edition of the Future 40.

“We are very excited at the idea of ​​closing this first institutional funding round with such renowned investors with in-depth knowledge of the pharmaceutical environment. With this funding, we can continue to develop our proprietary datasets and algorithms for the next generation of genomic therapy vectors and payloads. We look forward to bringing these solutions to our customers and partners,” said Julien Cottineau, co-founder and CSO of WhiteLab Genomics.

AI applied to genomics: strong development potential in a hundred billion dollar market

More than 4,000 human diseases, including Alzheimer’s disease, Parkinson’s disease, cystic fibrosis, cardiovascular disease, Duchenne muscular dystrophy and certain types of cancer, are caused by changes in the DNA sequence of an individual.

The WhiteLab Genomics technology aims to develop solutions to repair and replace these defective sequences. The growing field of genomic medicine should make it possible to treat these pathologies at the source, by stably replacing the need for drugs or surgery. The potential market is therefore extremely large, around one billion dollars

“Genomic therapies represent for us a very strong potential, and we have already invested in several companies at the intersection between AI and biotechnology. WhiteLab Genomics fits perfectly into this universe. We were impressed by what the company has achieved in two and a half years, and by its potential. We look forward to leading this exciting project together,” adds Renaud Poulard, Associate Director of Omnes Capital.

Hamzeh Abdul-Hadi, Investment Director at Debiopharm, adds: “David and Julien have brought together a unique team of data scientists and bioinformatics engineers. Leading research institutes such as Inserm and Généthon have placed their trust in them. This is why we are very happy to become shareholders of WhiteLab Genomics, and to be able to support the growth of this company”.

Source: White Lab Genomics

.

Back to top